Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (2+ Years)
NCT05153317Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jan 2022
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of elexacaftor, tezacaftor and ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) at 196 weeks. Started Jan 2022; status: completed.
02
Drugs
elexacaftortezacaftorivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT05153317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05153317.